Lucid Diagnostics Inc. (LUCD)

Market Cap	138.31M
Revenue (ttm)	4.40M
Net Income (ttm)	-65.84M
Shares Out	131.10M
EPS (ttm)	-0.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,099,111
Open	1.015
Previous Close	1.020
Day's Range	1.000 - 1.070
52-Week Range	0.750 - 1.800
Beta	1.22
Analysts	Strong Buy
Price Target	3.88 (+267.77%)
Earnings Date	Nov 12, 2025

About LUCD

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in a...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 14, 2021
• Employees: 72
• Stock Exchange: NASDAQ
• Ticker Symbol: LUCD
• Website: https://www.luciddx.com

Financial Performance

In 2024, Lucid Diagnostics's revenue was $4.35 million, an increase of 79.00% compared to the previous year's $2.43 million. Losses were -$53.03 million, 0.68% more than in 2023.

Analyst Summary

According to 4 analysts, the average rating for LUCD stock is "Strong Buy." The 12-month stock price target is $3.88, which is an increase of 267.77% from the latest price.

Price Target

$3.88

(267.77% upside)

Analyst Consensus: Strong Buy